$WGS
GeneDx Holdings Corp.

2022 Q4 Form 10-Q Financial Statement

#000181833122000078 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $61.35M $83.23M
YoY Change 6.14% 92.77%
Cost Of Revenue $77.68M $69.69M
YoY Change 28.17% 35.34%
Gross Profit -$16.33M $13.55M
YoY Change 481.97% -263.06%
Gross Profit Margin -26.62% 16.28%
Selling, General & Admin $68.75M $89.31M
YoY Change -22.4% 45.75%
% of Gross Profit 659.19%
Research & Development $15.22M $13.35M
YoY Change -31.58% -25.11%
% of Gross Profit 98.56%
Depreciation & Amortization $34.04M $6.995M
YoY Change 487.4% 27.39%
% of Gross Profit 51.63%
Operating Expenses $308.6M $102.7M
YoY Change 178.36% 29.78%
Operating Profit -$324.9M -$90.82M
YoY Change 180.6% 2.89%
Interest Expense $16.21M $806.0K
YoY Change -78.54% 18.01%
% of Operating Profit
Other Income/Expense, Net $0.00 $13.17M
YoY Change -100.0% -89.12%
Pretax Income -$308.7M -$77.65M
YoY Change 663.52% -347.34%
Income Tax $90.00K -$65.00K
% Of Pretax Income
Net Earnings -$308.8M -$77.58M
YoY Change 668.35% -337.03%
Net Earnings / Revenue -503.28% -93.21%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$26.34 -$0.20
COMMON SHARES
Basic Shares Outstanding 386.8M shares 380.6M shares
Diluted Shares Outstanding 380.8M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $123.9M $191.4M
YoY Change -69.07% -58.52%
Cash & Equivalents $123.9M $191.4M
Short-Term Investments
Other Short-Term Assets $6.390M $9.698M
YoY Change 68.07% 131.68%
Inventory $13.67M $44.17M
Prepaid Expenses $11.82M $17.52M
Receivables $42.63M $42.67M
Other Receivables $700.0K $1.194M
Total Short-Term Assets $212.6M $306.6M
YoY Change -56.03% -43.06%
LONG-TERM ASSETS
Property, Plant & Equipment $51.53M $84.37M
YoY Change -17.84% 39.84%
Goodwill $181.5M
YoY Change
Intangibles $186.7M $190.2M
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.485M $7.968M
YoY Change -6.42% 120.54%
Total Long-Term Assets $278.3M $522.4M
YoY Change 294.51% 705.55%
TOTAL ASSETS
Total Short-Term Assets $212.6M $306.6M
Total Long-Term Assets $278.3M $522.4M
Total Assets $490.9M $829.0M
YoY Change -11.4% 37.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $46.02M $40.12M
YoY Change 2.96% -7.38%
Accrued Expenses $38.86M $26.15M
YoY Change 96.68%
Deferred Revenue $40.00K $0.00
YoY Change -92.0% -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.750M $349.0K
YoY Change
Total Short-Term Liabilities $144.3M $162.3M
YoY Change 42.47% 126.69%
LONG-TERM LIABILITIES
Long-Term Debt $6.250M $10.65M
YoY Change -43.18% -3.17%
Other Long-Term Liabilities $22.00M $20.20M
YoY Change 0.42% -6.91%
Total Long-Term Liabilities $28.25M $30.85M
YoY Change -14.15% -5.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $144.3M $162.3M
Total Long-Term Liabilities $28.25M $30.85M
Total Liabilities $237.2M $267.7M
YoY Change 42.92% 26.06%
SHAREHOLDERS EQUITY
Retained Earnings -$1.124B -$815.7M
YoY Change 95.4% 52.39%
Common Stock $38.00K $38.00K
YoY Change 58.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $253.7M $561.3M
YoY Change
Total Liabilities & Shareholders Equity $490.9M $829.0M
YoY Change -11.4% 37.39%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$308.8M -$77.58M
YoY Change 668.35% -337.03%
Depreciation, Depletion And Amortization $34.04M $6.995M
YoY Change 487.4% 27.39%
Cash From Operating Activities -$64.66M -$88.36M
YoY Change 24.38% 24.56%
INVESTING ACTIVITIES
Capital Expenditures $2.840M -$4.278M
YoY Change -136.92% 18.24%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$2.840M -$4.278M
YoY Change -63.08% 18.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K -647.0K
YoY Change -106.8% -100.13%
NET CHANGE
Cash From Operating Activities -64.66M -88.36M
Cash From Investing Activities -2.840M -4.278M
Cash From Financing Activities 70.00K -647.0K
Net Change In Cash -67.43M -93.29M
YoY Change 11.07% -121.96%
FREE CASH FLOW
Cash From Operating Activities -$64.66M -$88.36M
Capital Expenditures $2.840M -$4.278M
Free Cash Flow -$67.50M -$84.08M
YoY Change 52.4% 24.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-39482
dei Entity Registrant Name
EntityRegistrantName
Sema4 Holdings Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001818331
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1966622
dei Entity Address Address Line1
EntityAddressAddressLine1
333 Ludlow Street
dei Entity Address Address Line2
EntityAddressAddressLine2
North Tower, 8th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Stamford
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06902
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
298-6470
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
386795130 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191360000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
400569000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42669000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26509000 usd
CY2022Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1194000 usd
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
54000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
44173000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
33456000 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17516000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
19154000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9698000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3802000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
306610000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
483544000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44033000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
84369000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62719000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
190156000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2022Q3 us-gaap Goodwill
Goodwill
181468000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
0 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
14370000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7968000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6930000 usd
CY2022Q3 us-gaap Assets
Assets
828974000 usd
CY2021Q4 us-gaap Assets
Assets
554093000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
86884000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
64801000 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1828000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2623000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
473000 usd
CY2022Q3 cmlf Lease Liabilities Current
LeaseLiabilitiesCurrent
4996000 usd
CY2021Q4 cmlf Lease Liabilities Current
LeaseLiabilitiesCurrent
0 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
68623000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
33387000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
162331000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
101284000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10651000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11000000 usd
CY2022Q3 cmlf Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
62336000 usd
CY2021Q4 cmlf Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
0 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20200000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21907000 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2603000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 usd
CY2022Q3 cmlf Warrant Liability
WarrantLiability
5059000 usd
CY2021Q4 cmlf Warrant Liability
WarrantLiability
21555000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4500000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
10244000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
267680000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
165990000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
380000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
381428905 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
381428905 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
242647604 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
242647604 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
38000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1376916000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
963520000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-815660000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-575441000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
561294000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
388103000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
828974000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
554093000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83234000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43178000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
173344000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154394000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
69685000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
51487000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
183768000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
168190000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
13549000 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
-8309000 usd
us-gaap Gross Profit
GrossProfit
-10424000 usd
us-gaap Gross Profit
GrossProfit
-13796000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13354000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17831000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61837000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82916000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
37451000 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28152000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
103116000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
82092000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51863000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33125000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
162681000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
148033000 usd
CY2022Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
1697000 usd
CY2021Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
847000 usd
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
4712000 usd
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
3532000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-90816000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-88264000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-342770000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-330369000 usd
CY2022Q3 cmlf Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
12978000 usd
CY2021Q3 cmlf Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
122171000 usd
cmlf Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
54350000 usd
cmlf Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
122171000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
996000 usd
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1405000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
57000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
806000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
683000 usd
us-gaap Interest Expense
InterestExpense
2404000 usd
us-gaap Interest Expense
InterestExpense
2128000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-520000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5064000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13170000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
120995000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
53409000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
125164000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77646000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32731000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-289361000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-205205000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-65000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49142000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77581000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77581000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
32731000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
32731000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-240219000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
us-gaap Net Income Loss
NetIncomeLoss
-205205000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-205205000 usd
CY2022Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
637274000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77581000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77581000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77581000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Description of Business <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sema4 Holdings Corp. (“Sema4 Holdings”) through its subsidiaries Sema4 OpCo, Inc., formerly Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”) and GeneDx Holding 2, LLC, provides genomics-related diagnostic and information services and pursues genomics medical research. Sema4 utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. Sema4 provides a variety of genetic diagnostic tests, and screening solutions, and information with a focus on pediatrics, hereditary cancer screening, and rare diseases for children and adults. Sema4 Holdings’ operating subsidiaries primarily serve healthcare professionals who work with their patients and bills third-party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in New York, California, Florida, Connecticut and Illinois. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Business Combination Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Business Combination Merger” and, together with the other transactions contemplated by the Business Combination Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Business Combination Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Business Combination Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination Merger (1 share of Legacy Sema4 Class A common stock for 123.8339 shares of Sema4 Holdings Class A common stock (the “Class A common stock”) (the “Conversion Ratio”).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Business Combination Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 29, 2022, the Company consummated the transactions contemplated by that certain Agreement and Plan of Merger, dated as of January 14, 2022 (as amended, the “ Acquisition Merger Agreement”), by and among the Company and GeneDx, Inc. (“GeneDx”), a New Jersey corporation and wholly-owned subsidiary of OPKO Health, Inc. (“OPKO”), GeneDx Holding 2, Inc., which held 100% of GeneDx (“Holdco2”), at the Effective Time (as defined in the Acquisition Merger Agreement) and OPKO, which provided for, among other things, the acquisition of GeneDx from OPKO. After giving effect to the mergers and the other transactions contemplated by the Acquisition Merger Agreement (the “Acquisition”), GeneDx was converted into a Delaware limited liability company and became the Company’s wholly-owned indirect subsidiary.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, “Business Combination,” for additional details regarding the Business Combination and Acquisition.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “Sema4” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) Sema4 Holdings and its subsidiaries following the consummation of the Business Combination.</span></div>
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
329000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1272000 usd
CY2022Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
561294000 usd
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
388103000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-240219000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2199000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41552000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
197659000 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
172000000 usd
CY2022Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
561294000 usd
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
171535213 shares
CY2021Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
334439000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-566504000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
32731000 usd
CY2021Q3 cmlf Temporary Equity Elimination As Part Of Reorganization Shares
TemporaryEquityEliminationAsPartOfReorganizationShares
171535213 shares
CY2021Q3 cmlf Temporary Equity Elimination As Part Of Reorganization
TemporaryEquityEliminationAsPartOfReorganization
334439000 usd
CY2021Q3 cmlf Stock Issued During Period Conversion Of Temporary Equity As Part Of Reorganization
StockIssuedDuringPeriodConversionOfTemporaryEquityAsPartOfReorganization
104532000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-744000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
510751000 usd
CY2021Q3 cmlf Share Based Compensation Modification Reclassification
ShareBasedCompensationModificationReclassification
304837000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5418000 usd
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
391021000 usd
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
171535213 shares
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
334439000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-330051000 usd
us-gaap Net Income Loss
NetIncomeLoss
-205205000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1483000 usd
cmlf Temporary Equity Elimination As Part Of Reorganization Shares
TemporaryEquityEliminationAsPartOfReorganizationShares
171535213 shares
cmlf Temporary Equity Elimination As Part Of Reorganization
TemporaryEquityEliminationAsPartOfReorganization
334439000 usd
cmlf Stock Issued During Period Conversion Of Temporary Equity As Part Of Reorganization
StockIssuedDuringPeriodConversionOfTemporaryEquityAsPartOfReorganization
104532000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-744000 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
510751000 usd
cmlf Share Based Compensation Modification Reclassification
ShareBasedCompensationModificationReclassification
304837000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5418000 usd
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
391021000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
us-gaap Net Income Loss
NetIncomeLoss
-205205000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
25269000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
16012000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
41553000 usd
cmlf Redemption Price Per Warrant
RedemptionPricePerWarrant
0.01
us-gaap Share Based Compensation
ShareBasedCompensation
182454000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-54350000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-122171000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-49176000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-301000 usd
us-gaap Inventory Write Down
InventoryWriteDown
732000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1122000 usd
cmlf Noncash Lease Expense
NoncashLeaseExpense
1112000 usd
cmlf Noncash Lease Expense
NoncashLeaseExpense
1174000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
387000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5491000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10787000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5239000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7334000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5153000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15710000 usd
cmlf Increase Decrease In Due To From Related Parties
IncreaseDecreaseInDueToFromRelatedParties
-1935000 usd
cmlf Increase Decrease In Due To From Related Parties
IncreaseDecreaseInDueToFromRelatedParties
-124000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1355000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
17000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
28557000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4927000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-473000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1290000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-10008000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-3375000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-254501000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-138449000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
127004000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
cmlf Number Of Days For Written Notice Of Redemption
NumberOfDaysForWrittenNoticeOfRedemption
30 d
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4990000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4344000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
6494000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
8749000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-138488000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13093000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
350000000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
197659000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
0 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
442684000 usd
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
0 usd
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
230665000 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
0 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
51760000 usd
cmlf Payment For Settlement Of Unvested Stock Appreciation Rights
PaymentForSettlementOfUnvestedStockAppreciationRights
0 usd
cmlf Payment For Settlement Of Unvested Stock Appreciation Rights
PaymentForSettlementOfUnvestedStockAppreciationRights
3795000 usd
us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
0 usd
us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
8741000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2632000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2960000 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
0 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
1000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2223000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
995000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
197250000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
494758000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-195739000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
343216000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
401469000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118960000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205730000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
462176000 usd
us-gaap Interest Paid Net
InterestPaidNet
1795000 usd
us-gaap Interest Paid Net
InterestPaidNet
2128000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
487000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
50000 usd
us-gaap Stock Issued1
StockIssued1
172000000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1546000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
193000 usd
cmlf Software Development Costs Incurred But Not Yet Paid
SoftwareDevelopmentCostsIncurredButNotYetPaid
448000 usd
cmlf Software Development Costs Incurred But Not Yet Paid
SoftwareDevelopmentCostsIncurredButNotYetPaid
1228000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the capitalization of software costs, the valuation of stock-based awards, inventory, earn-out contingent liabilities and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. </span></div>The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of September 30, 2022 and December 31, 2021 were primarily from large managed care insurance companies and a reference laboratory. There was no individual patient that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate customer credit risk.
CY2020 cmlf Proceeds From Government Assistance
ProceedsFromGovernmentAssistance
5400000 usd
CY2020Q4 us-gaap Accrued Payroll Taxes Current And Noncurrent
AccruedPayrollTaxesCurrentAndNoncurrent
3800000 usd
CY2021Q4 cmlf Payment Of Deferred Payroll Taxes
PaymentOfDeferredPayrollTaxes
1900000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
400000 usd
cmlf Common Stock Threshold Trading Days
CommonStockThresholdTradingDays
30 d
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
221604000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191360000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
400569000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
14370000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205730000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
401469000 usd
CY2022Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
83234000 usd
CY2021Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
72953000 usd
CY2022Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
3600000 usd
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21995000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21994972 shares
CY2022Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q3 cmlf Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption
ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption
18.00
CY2021 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
2300000 usd
CY2021Q1 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
100000 usd
CY2021Q2 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
100000 usd
CY2021Q3 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
800000 usd
CY2021Q4 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
1300000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43178000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
173344000 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
236618000 usd
CY2022Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-77581000 usd
CY2021Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
22673000 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-318492000 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-195315000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83234000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154394000 usd
CY2022Q2 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-30100000 usd
CY2021 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-24200000 usd
CY2022Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
7600000 usd
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P2Y6M
cmlf Revenue Recognized Included Contract Liability
RevenueRecognizedIncludedContractLiability
2100000 usd
CY2022Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
300000 usd
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3296000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3769000 usd
cmlf Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
1861000 usd
cmlf Contract With Customer Amount Transferred To Received
ContractWithCustomerAmountTransferredToReceived
800000 usd
cmlf Contract With Customer Liability Prepayments
ContractWithCustomerLiabilityPrepayments
737000 usd
cmlf Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
1682000 usd
cmlf Contract With Customer Asset Other Increase Decrease
ContractWithCustomerAssetOtherIncreaseDecrease
-92000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4265000 usd
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2824000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1400000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
500000 usd
CY2022Q3 cmlf Revenue Recognized Included Contract Liability
RevenueRecognizedIncludedContractLiability
700000 usd
CY2021Q3 cmlf Revenue Recognized Included Contract Liability
RevenueRecognizedIncludedContractLiability
300000 usd
cmlf Revenue Recognized Included Contract Liability
RevenueRecognizedIncludedContractLiability
1700000 usd
CY2021Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
1800000 usd
CY2022Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
500000 usd
CY2021Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
300000 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1500000 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
900000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191400000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
200000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10200000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-200000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-10200000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
155700000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
114625000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
71331000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51906000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
84369000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62719000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000000.0 usd
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5500000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19400000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000000.0 usd
CY2022Q3 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
1700000 usd
CY2021Q3 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
1400000 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
5000000.0 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
4000000.0 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6995000 usd
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5491000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19425000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16012000 usd
CY2022Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
600000 usd
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1000000 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
875000 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2131000 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2174000 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2218000 usd
CY2022Q3 cmlf Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
3602000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
11000000 usd
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
349000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10651000 usd
CY2022Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
900000 usd
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
900000 usd
CY2022Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P9Y
CY2022Q3 cmlf Lessee Finance Lease Interest Rate
LesseeFinanceLeaseInterestRate
0.131
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3400000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18400000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44033000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
11372000 usd
CY2022Q3 cmlf Lease Assets
LeaseAssets
55405000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45134000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17202000 usd
CY2022Q3 cmlf Lease Liabilities
LeaseLiabilities
67755000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
4762000 usd
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
116000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
422000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
140000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
419000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2056000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
5603000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
912000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2736000 usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
547000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1630000 usd
CY2022Q3 cmlf Finance Lease Costs
FinanceLeaseCosts
1459000 usd
cmlf Finance Lease Costs
FinanceLeaseCosts
4366000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
3515000 usd
us-gaap Lease Cost
LeaseCost
9969000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1409000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1170000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability To Be Paid Remainder Of Fiscal Year
LesseeOperatingAndFinanceAndLiabilityToBePaidRemainderOfFiscalYear
2579000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4589000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3584000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability To Be Paid Year One
LesseeOperatingAndFinanceAndLiabilityToBePaidYearOne
8173000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5504000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
2763000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability To Be Paid Year Two
LesseeOperatingAndFinanceAndLiabilityToBePaidYearTwo
8267000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5925000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
2451000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability To Be Paid Year Three
LesseeOperatingAndFinanceAndLiabilityToBePaidYearThree
8376000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6066000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
2003000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability To Be Paid Year Four
LesseeOperatingAndFinanceAndLiabilityToBePaidYearFour
8069000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
57511000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
49884000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability To Be Paid Year Five
LesseeOperatingAndFinanceAndLiabilityToBePaidYearFive
107395000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
81004000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
61855000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability To Be Paid
LesseeOperatingAndFinanceAndLiabilityToBePaid
142859000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
32997000 usd
CY2022Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
42107000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability Undiscounted Excess Amount
LesseeOperatingAndFinanceAndLiabilityUndiscountedExcessAmount
75104000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
48007000 usd
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
19748000 usd
CY2022Q3 cmlf Lessee Operating And Finance And Liability
LesseeOperatingAndFinanceAndLiability
67755000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y4M24D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P19Y
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.110
us-gaap Operating Lease Payments
OperatingLeasePayments
4146000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1630000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2632000 usd
CY2022Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
8900000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
2.20
CY2022Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
51800000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
900000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1273000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18011000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
41553000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
182454000 usd
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49100000 usd
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0019
CY2022Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-48600000 usd
CY2022Q2 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-48600000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77581000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
32731000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
32731000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
380764176 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185680394 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
24650552 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
380764176 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
210330946 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-240219000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
us-gaap Net Income Loss
NetIncomeLoss
-205205000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-205205000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
321461266 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
321461266 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63121738 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63121738 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.25
cmlf Reverse Recapitalization Exchange Ratio
ReverseRecapitalizationExchangeRatio
123.8339
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
97114874 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38326784 shares
CY2022Q3 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
250 position
CY2022Q3 cmlf Restructuring And Related Cost Expected Number Of Positions Eliminated Percent
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent
0.13
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
0 usd
us-gaap Restructuring Charges
RestructuringCharges
18554000000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
8759000000 usd
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
9795000000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
40122000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
44693000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26147000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19758000 usd
CY2022Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
20100000 usd
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
515000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
350000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
86884000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
64801000 usd
CY2022Q3 us-gaap Accrued Insurance Noncurrent
AccruedInsuranceNoncurrent
19700000 usd
cmlf Reserve For Refunds To Insurance Carriers Term
ReserveForRefundsToInsuranceCarriersTerm
P4Y
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
13026000 usd
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
13561000 usd
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8135000 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7013000 usd
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3138000 usd
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1057000 usd
CY2022Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
1790000 usd
CY2021Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
2826000 usd
CY2022Q3 cmlf Indemnification Liabilities
IndemnificationLiabilities
13470000 usd
CY2021Q4 cmlf Indemnification Liabilities
IndemnificationLiabilities
0 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
19890000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 usd
CY2022Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
9174000 usd
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
8930000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
68623000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
33387000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
181184000 usd
CY2022Q3 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
284000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
181468000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
196000000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
190156000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3505000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
14025000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
14025000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
14025000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
14025000 usd
CY2022Q3 cmlf Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
130551000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
190156000 usd

Files In Submission

Name View Source Status
0001818331-22-000078-index-headers.html Edgar Link pending
0001818331-22-000078-index.html Edgar Link pending
0001818331-22-000078.txt Edgar Link pending
0001818331-22-000078-xbrl.zip Edgar Link pending
ceocertificationfor-ex311x.htm Edgar Link pending
ceocertificationfor-ex321x.htm Edgar Link pending
cfocertificationfor-ex312x.htm Edgar Link pending
cfocertificationfor-ex322x.htm Edgar Link pending
cmlf-20220930.htm Edgar Link pending
cmlf-20220930.xsd Edgar Link pending
cmlf-20220930_g1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
cmlf-20220930_cal.xml Edgar Link unprocessable
cmlf-20220930_pre.xml Edgar Link unprocessable
cmlf-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cmlf-20220930_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cmlf-20220930_lab.xml Edgar Link unprocessable